These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33413474)

  • 1. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.
    Liu J; Huang X; Liu H; Wei C; Ru H; Qin H; Lai H; Meng Y; Wu G; Xie W; Mo X; Johnson CH; Zhang Y; Tang W
    J Transl Med; 2021 Jan; 19(1):27. PubMed ID: 33413474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model.
    Huang Z; Huang X; Huang Y; Liang K; Chen L; Zhong C; Chen Y; Chen C; Wang Z; He F; Qin M; Long C; Tang B; Huang Y; Wu Y; Mo X; Weizhong T; Liu J
    Microbiol Spectr; 2024 May; 12(5):e0272023. PubMed ID: 38572984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
    Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
    J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
    Eilertsen IA; Sveen A; Strømme JM; Skotheim RI; Nesbakken A; Lothe RA
    Int J Cancer; 2019 Feb; 144(4):841-847. PubMed ID: 30121958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
    Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
    Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated multi-omics characterization of KRAS mutant colorectal cancer.
    Chong W; Zhu X; Ren H; Ye C; Xu K; Wang Z; Jia S; Shang L; Li L; Chen H
    Theranostics; 2022; 12(11):5138-5154. PubMed ID: 35836817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers.
    Liu X; Xu X; Wu Z; Shan Q; Wang Z; Wu Z; Ding X; Huang W; Wang Z
    Front Immunol; 2022; 13():961350. PubMed ID: 36172359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence.
    Kocián P; Šedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Špíšek R; Fialová A
    Hum Immunol; 2011 Nov; 72(11):1022-8. PubMed ID: 21884745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
    Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
    Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer.
    Ye L; Zhang T; Kang Z; Guo G; Sun Y; Lin K; Huang Q; Shi X; Ni Z; Ding N; Zhao KN; Chang W; Wang J; Lin F; Xue X
    Front Immunol; 2019; 10():2368. PubMed ID: 31681276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.